[go: up one dir, main page]

WO2008126085A3 - Method for treating bone marrow disorders - Google Patents

Method for treating bone marrow disorders Download PDF

Info

Publication number
WO2008126085A3
WO2008126085A3 PCT/IL2008/000503 IL2008000503W WO2008126085A3 WO 2008126085 A3 WO2008126085 A3 WO 2008126085A3 IL 2008000503 W IL2008000503 W IL 2008000503W WO 2008126085 A3 WO2008126085 A3 WO 2008126085A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone marrow
treating bone
marrow disorders
present
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2008/000503
Other languages
French (fr)
Other versions
WO2008126085A2 (en
Inventor
Elena Feinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of WO2008126085A2 publication Critical patent/WO2008126085A2/en
Anticipated expiration legal-status Critical
Publication of WO2008126085A3 publication Critical patent/WO2008126085A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods for the treatment of bone marrow disorders including myelodysplastic syndromes and adult and pediatric leukemias. The methods comprise systemically administering an oligonucleotide which reduces or inhibits expression of a gene associated with a bone marrow disorder to a subject in need thereof. The present invention further provides the use of an oligonucleotide inhibitor for the preparation of a medicament for promoting recovery in a subject suffering from a bone marrow disorder.
PCT/IL2008/000503 2007-04-12 2008-04-13 Method for treating bone marrow disorders Ceased WO2008126085A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92307407P 2007-04-12 2007-04-12
US60/923,074 2007-04-12

Publications (2)

Publication Number Publication Date
WO2008126085A2 WO2008126085A2 (en) 2008-10-23
WO2008126085A3 true WO2008126085A3 (en) 2010-02-25

Family

ID=39864455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/000503 Ceased WO2008126085A2 (en) 2007-04-12 2008-04-13 Method for treating bone marrow disorders

Country Status (1)

Country Link
WO (1) WO2008126085A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC EXOSOME FOR THE OUTPUT OF THERAPEUTIC ACTIVE SUBSTANCES
CN116059234A (en) * 2022-12-15 2023-05-05 东南大学 Application of Rps14 gene, drug and construction method of mouse model

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069056A1 (en) * 2004-09-28 2006-03-30 Elena Feinstein Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US20070078085A1 (en) * 2004-10-13 2007-04-05 Chung Leland W Methods and compositions for the utilization and targeting of osteomimicry

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069056A1 (en) * 2004-09-28 2006-03-30 Elena Feinstein Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US20070078085A1 (en) * 2004-10-13 2007-04-05 Chung Leland W Methods and compositions for the utilization and targeting of osteomimicry

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DYKXHOORN ET AL.: "Determinants of specific RNA interference-mediated silencing of human beta- globin alleles differing by a single nucleotide polymorphism.", PNAS, vol. 103, April 2006 (2006-04-01), pages 5953 - 5958, XP008162018, DOI: doi:10.1073/pnas.0601309103 *
HSU ET AL.: "Targeted siRNA inhibition of NPM-ALK in anaplastic large cell lymphoma causes disease specific growth inhibition which augments chemotherapeutic agents.", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, June 2005 (2005-06-01), pages 9517 *
JAMES ET AL.: "A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera.", NATURE, vol. 434, April 2005 (2005-04-01), pages 1144 - 1148 *
LIANG ET AL.: "Silencing of CXCR4 blocks breast cancer metastasis.", CANCER RES., vol. 65, February 2005 (2005-02-01), pages 967 - 971 *
NAVAS ET AL.: "Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.", BLOOD, vol. 108, December 2006 (2006-12-01), pages 4170 - 4177 *
WALTERS ET AL.: "RNAi-induced down-regulation of FLT3 expression in AML cell lines Increases sensitivity to MLN518.", BLOOD, vol. 105, April 2005 (2005-04-01), pages 2952 - 2954 *
ZHU ET AL.: "Fibrobalst growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosls in multiple myeloma.", MOL CANCER THER., vol. 4, 2005, pages 787 - 798 *

Also Published As

Publication number Publication date
WO2008126085A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2013061161A3 (en) New combination therapies for treating neurological disorders
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MY162067A (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2008048471A3 (en) Obstructive sleep apnea treatment devices, systems and methods
WO2009148605A3 (en) Methods for treating hypercholesterolemia
WO2007089945A3 (en) Treating diseases by targeting silt3
EP2963116A3 (en) Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
MX2019005130A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin.
MX2009002921A (en) Azetidinone derivatives for the treatment of disorders of the lipid metabolism.
WO2009045464A8 (en) Methods of treating neurological autoimmune disorders with cyclophosphamide
WO2007100675A3 (en) Collagenase for treating cellulite
WO2010065662A3 (en) Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
HRP20192130T1 (en) COMBINATION THERAPY FOR THE TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND STROKE
MX2019002669A (en) Methods of treating behavioral symptoms of neurological and mental disorders.
WO2007029249A3 (en) Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2010059371A3 (en) Apparatus and method for ultrasonic spine treatment
WO2012074561A3 (en) Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
EP2064347A4 (en) Methods for the identification, evaluation and treatment of patients having cc-chemokine receptor 2(ccr-2) mediated disorders
WO2006124681A3 (en) Oral drug delivery system and methods of use thereof
EP2252608A4 (en) Method for treating pain syndrome and other disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08738205

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08738205

Country of ref document: EP

Kind code of ref document: A2